What technology area does this patent fall under?

Primary CPC classification C07D515/22. Mapped technology areas include Chemistry & Metallurgy.

When was this patent published?

Publication date Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).

MCL-1 inhibitors and methods of use thereof

US9840518B2 · US · B2

Patent metadata
Field	Value
Publication number	US-9840518-B2
Application number	US-201715493210-A
Country	US
Kind code	B2
Filing date	Apr 21, 2017
Priority date	Apr 22, 2016
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 4,7 .0 11,15 .0 16,21 .0 20,24 .0 30,35 ]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 4,7 .0 11,15 .0 16,21 .0 20,24 .0 30,35 ]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound having the structure of (R a )-(+)17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 4,7 .0 11,15 .0 16,21 .0 20,24 .0 30,35 ]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula II) or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 . 3. The pharmaceutically acceptable salt of the compound of claim 1 . 4. A pharmaceutical composition comprising (R a )-(+)17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 4,7 .0 11,15 .0 16,21 .0 20,24 .0 30,35 ]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula II) or a pharmaceutically acceptable salt thereof and a pharmaceutical excipient, carrier or diluent.

Assignees

Astrazeneca Ab

Inventors

Classifications

A61P35/00
Antineoplastic agents · CPC title
A61P35/02
specific for leukemia · CPC title
A61K31/395
having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins · CPC title
C07D515/22Primary
in which the condensed system contains four or more hetero rings · CPC title
C07D497/22Primary
in which the condensed system contains four or more hetero rings · CPC title

Patent family

Related publications grouped by family.

View patent family 58664658

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9840518B2 cover?: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.1 4,7 .0 11,15 .0 16,21 .0 20,24 .0 30,35 ]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical composi…
Who is the assignee on this patent?: Astrazeneca Ab
What technology area does this patent fall under?: Primary CPC classification C07D515/22. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?: Publication date Tue Dec 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).